Guess the smart money must think differently about EX1's claims to having the leading technology in exosomes with Lonza buying Codiak's exosome manufacturing facility. Lonza has also recently bought Exosomics. So this is the year we LEAP. Yep, sure.
- Forums
- ASX - By Stock
- TYP
- Tell me another one....
Tell me another one....
Featured News
Add TYP (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.4¢ |
Change
0.007(14.9%) |
Mkt cap ! $63.78M |
Open | High | Low | Value | Volume |
4.8¢ | 5.7¢ | 4.7¢ | $523.5K | 10.18M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6200 | 5.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.5¢ | 150000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6200 | 0.054 |
2 | 137000 | 0.053 |
3 | 307255 | 0.052 |
2 | 58035 | 0.051 |
3 | 342718 | 0.050 |
Price($) | Vol. | No. |
---|---|---|
0.055 | 150000 | 2 |
0.057 | 300000 | 1 |
0.058 | 200000 | 1 |
0.059 | 298803 | 2 |
0.060 | 46352 | 4 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
TYP (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online